Psilocin shows early promise in Entropy’s eating disorder trial
Eating disorders has become a major health concern in Australia and globally, with 1.1m, or 4.45% of Australians living with an eating disorder in 2023, up by 21% since 2012Entropy investigating whether its novel…

- Eating disorders has become a major health concern in Australia and globally, with 1.1m, or 4.45% of Australians living with an eating disorder in 2023, up by 21% since 2012
- Entropy investigating whether its novel IV-infused psilocin candidate TRP-8803 could offer new treatment approach to eating disorders
- The company is undertaking a phase II study of TRP-8803 for binge eating disorder (BED), with encouraging early results
The prevalence of eating disorders is on the rise. A Global Burden of Disease analysis estimated that 18.1 million people worldwide were living with anorexia nervosa or bulimia nervosa in 2023, an increase of 71% since 1990.
The number is expected to reach 21.8m by 2050 with Australia at the epicentre, prompting concern among health professionals, federal and state governments.
The study found that Australia’s estimated rate of more than 1000 per 100,000 people is over four times the global average.
According to the Butterfly Foundation, the global study was likely just scratching the surface of the true burden of eating disorders in Australia, given that only anorexia and bulimia were included.
The foundation is Australia’s leading charity supporting people affected by eating disorders and body image concerns, along with their families and carers.
The organisation said most people in Australia with eating disorders experience other conditions, such as binge eating disorder (BED) and other specified feeding and eating disorders (OSFED).
In some more concerning stats, according to the Paying the Price, Second Edition report by Deloitte and commissioned by the Butterfly Foundation, there were 1.1m, or 4.45% of Australians living with an eating disorder in 2023, up by 21% since 2012.
The report found the total economic and social cost of eating disorders was $66.9 billion in 2023, equivalent to $60,654 per person with an eating disorder.
High risk of mortality
Eating disorders are also stubbornly hard to treat and carry some of the highest mortality rates among psychiatric illnesses.
Anorexia nervosa carries the highest mortality rate of any eating disorder, with cardiovascular complications the leading cause of death, followed by suicide.
While bulimia and BED have lower death rates, they are still significantly higher than in the general population.
While historically viewed as illnesses primarily affecting females, the prevalence of eating disorders in men is also being increasingly recognised.
BED, characterised by regular episodes of binge eating, is the third most common eating disorder in Australia and affects men and women in roughly equal numbers.
New approach to treating eating disorder
With the growing prevalence of eating disorders, Entropy Neurodynamics (ASX:ENP) is working to improve treatments with its novel IV-infused psilocin candidate TRP-8803.
ENP is undertaking a phase II study of TRP-8803 for the treatment of BED in conjunction with Swinburne University of Technology, with the Butterfly Foundation assisting with recruitment efforts.
The company also plans to research the use of TRP-8803 in anorexia in a phase 1b/2a multi-indication basket trial.
Psilocin is the active metabolite of psilocybin, the psychedelic compound found in so-called ‘magic mushrooms’.
ENP has developed TRP-8803 to address key limitations associated with oral psilocybin administration, aiming to deliver a rapid onset and more precise control over treatment duration, intensity and the predictability of the psychedelic experience.
In July, ENP released positive topline safety and efficacy results from Cohort 1 of the phase II trial in BED, which involved a 140-minute infusion of TRP-8803.
All six Cohort 1 patients achieved clinically meaningful improvement, including clinical remission in 50% of patients, defined as zero binge-eating episodes in the four weeks after treatment.
Across the six patients, weekly binge-eating episodes fell by 74%.
Anxiety and depression scores also fell, while life satisfaction rose within four weeks.
ENP said the improvements were comparable to those seen over longer periods in successful SSRI studies.
Giving hope in unmet need of eating disorders
CEO Jason Carroll told Stockhead the early BED trial results suggest that a precisely controlled IV treatment warranted further investigation.
“Because of the small, open label study design, while we can’t yet definitively state that TRP-8803 works, we have reason to be highly encouraged by what we’ve seen so far,” he said.
“But we saw significant results in six out of six patients.”
Carroll said there was so much unmet need and so few products that work in the treatment of eating disorders, with patients often suffering for many years.
“Eating disorders are among the most complex psychiatric conditions,” he said.
Treatment can involve years of psychological therapy and nutritional rehabilitation, with repeated hospital admissions often needed when a patient’s physical health is compromised by the disorder.
For many, recovery is a long and challenging process, not only for the individual but also for their loved ones, with limited options when existing approaches fail.
ENP’s phase II BED trial treatment with IV-psilocin is being done in conjunction with psychotherapy.
“The discussion takes place beforehand, to prepare the patient, and afterwards, to talk through what happened,” Carroll said.
“We believe eating disorders involve dysfunction in brain networks and very rigid patterns of thinking and behaviour.
“Patients can become trapped in obsessive-compulsive loops.
“If you can change those network dynamics and help patients to find new ways of coping, you may be able to change their outlook.”
Looking for predictive brain biomarkers
Carroll said electroencephalography (EEG) was being used in the trial to measure how the brain changes before, during and after treatment.
“We are seeing changes in brain networks within the first 11 minutes of the infusion,” he said.
“We’re trying to identify predictive brain biomarkers that could help us understand a patient’s likely outcome.
“Ultimately, we hope that by measuring someone’s brain activity before treatment, we may be able to predict what psychedelic therapy could deliver for them.
“That would be pretty special, if the data comes through well, of course.”
‘Need to see more treatment options’
The Butterfly Foundation’s head of communications and engagement Mel Wilton told Stockhead eating disorders were complex mental illnesses influenced by a combination of biological, psychological and sociocultural risk factors.
“In Australia, less than 1 in 3 people with eating disorders are able to access the help they need, and the number of people impacted is only growing,” she said.
“Stigma and shame stop many from seeking support, but many others face barriers to care including cost, lack of availability, and living in rural and regional areas.
“We absolutely need to see more treatment options, and further research into new and evolving treatments, if we are to ever create an Australia free of eating disorders.”
For eating disorder support, contact the Butterfly National Helpline on 1800 ED HOPE (1800 33 4673) or visit butterfly.org.au
This story does not constitute financial product advice. You should consider obtaining independent advice before making any financial decision.
At Stockhead we tell it like it is. While Entropy Neurodynamics is a Stockhead advertiser, the company did not sponsor this article.
The post Psilocin shows early promise in Entropy’s eating disorder trial appeared first on Stockhead.
Figures reflect the source report and its stated period. This article is for information and is not investment advice.



